Phase IV, Multi-center, Randomized, Cross-over Study to Demonstrate the Efficacy of Pudendal Neuromodulation for the Treatment of Neurogenic Overactive Bladder
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Neurogenic Overactive Bladder
- Sponsor
- MedtronicNeuro
- Enrollment
- 17
- Locations
- 8
- Primary Endpoint
- Functional Bladder Capacity
- Status
- Terminated
- Last Updated
- 7 years ago
Overview
Brief Summary
The study is designed to demonstrate that treatment with low level stimulation of the bladder muscles reduces symptoms of urinary incontinence in comparison with no stimulation.
Detailed Description
The Medtronic InterStim device delivers stimulation therapy for the treatment of chronic intractable (functional) disorders of the pelvis and lower urinary or intestinal tract through the sacral nerve or the pudendal nerve systems. This trial is designed to demonstrate that neuromodulation of the pudendal nerve will effectively treat patients with neurogenic overactive bladder. Symptoms of urinary incontinence are compared when stimulation is switched on for 4 weeks to stimulation switched off for 4 weeks. After the eight week crossover period, all patients receive treatment and are followed up within the study for 12 months post implant.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Incomplete upper motor neuron lesion
- •Detrusor overactivity
- •Two leaks or two notices of leaks per day
- •Mean functional bladder capacity (volume voided per episode) of ≥100 ml
Exclusion Criteria
- •Complete spinal lesion or complete bilateral lesion of sacral / pudendal nerves.
- •Degenerative disease of the central nervous system
Outcomes
Primary Outcomes
Functional Bladder Capacity
Time Frame: Baseline, 4 weeks after implant, 8 weeks after implant
Functional Bladder capacity is measured as the average passed volume per episode, in milliliters, as recorded in the patient's voiding diary during the observation period. Due to the small number of patients in each group, the summary on the functional bladder capacity was provided for the combined groups.